Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents

Shungu, D L; Nalin, David R.; Gilman, Robert H.; Gadebusch, Hans H.; Cerami, A; Gill, Charles; Weissberger, Barbara

doi:10.1128/aac.31.6.949

Cited by 22 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bismuth citrate was active against all of the strains tested, and these MICs agree well with those previously reported by several investigators (8,22,36). Cimetidine, ranitidine, and famotidine were almost inactive, and these results are also in agreement with those reported elsewhere (8,32). In contrast to these histamine H2 receptor antagonists, two proton pump inhibitors, omeprazole and lansoprazole, showed considerable activities.…”

Section: Resultssupporting

confidence: 81%

“…In vitro, a number of antibiotics, including P-lactams, macrolides, and quinolones, have been known to be highly active against H. pylori (1,8,10,13,22,30,32,33,36). However, when tested as single agents in clinical studies, erythromycin (23), doxycycline (35), ofloxacin (5), ciprofloxacin (34), and norfloxacin (24) have not succeeded in eradicating H. pylori.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Iwahi

Satoh

Nakao

et al. 1991

Antimicrob Agents Chemother

269

156

View full text Add to dashboard Cite

The activities of various types of antiulcer agents against Helicobacter pylori (formerly called Campylobacter pylon) strains were determined by an agar dilution method. Among the compounds tested, two benzimidazole proton pump inhibitors, lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 ,ug/ml, and fourfold more potent than that of omeprazole. A major metabolite and two acid-converted rearrangement products of lansoprazole also exhibited good activities comparable or superior to that of the parent compound. Exposure to lansoprazole of H. pylori growing in a liquid medium led to an extensive loss of viability without a reduction in culture turbidity and produced an aberrant bacterial morphology characterized by the irregular constriction of cells and the collapse of cell surface structures. The antibacterial activity of lansoprazole and its related compounds was selective against H. pylori; common aerobic and anaerobic bacteria and Campylobacterjejuni were not inhibited by 100 ,ug/ml.

show abstract

Section: Resultssupporting

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Iwahi

Satoh

Nakao

et al. 1991

Antimicrob Agents Chemother

269

156

View full text Add to dashboard Cite

show abstract

“…venerealis, and C. hyointestinalis, for which MICs are 128 to 256 pug/ml (48). One of us found C. pylori strains to be resistant to intermediate levels of nalidixic acid (MIC, 48 ,ug/ml) (46), although others (36) have noted a wider range of susceptibilities (MIC, 4 to 128 ,ug/ml). In vitro activities of the fluoroquinolones against Campylobacter species have been reported by a number of workers (8,12,13,36).…”

Section: Quinolone Resistancementioning

confidence: 99%

Mechanisms of antibiotic resistance in Campylobacter species

Taylor

Courvalin

1988

Antimicrob Agents Chemother

150

105

View full text Add to dashboard Cite

“…pylori is susceptible to amoxicillin, ampicillin, carbenicillin, cefamandole, cefoxitin, cephalothin, cephradine, chloramphenicol, ciprofloxacin, clindamycin, clorobiocin, CP 62993, doxycycline, erythromycin, gentamicin, imipenem, kanamycin, minocycline, nifuroxazide, nitrofurantoin, norfloxacin, ofloxacin, oxolinic acid, rifampin, roxithromycin, tetracycline, and tobramycin (2,10,16,36,57,78,80,86,117,123,128). Most isolates are resistant to colistin, nalidixic acid, trimethoprim, sulfonamides, vancomycin, and polymyxin B (10,57,78,80,117,123), and some are resistant to cefaclor, metronidazole, and penicillin (78,86,128). Since drugs such as cimetidine and bismuth compounds have been used for treating gastric disease for a number of years, there has been significant interest in examining the in vitro activity of these agents against C. pylori.…”

Section: Gastric Diseasesmentioning

confidence: 99%

Campylobacter pylori and gastroduodenal disease

Buck

1990

Clin Microbiol Rev

139

View full text Add to dashboard Cite

Campylobacter pylori is a newly described, spiral-shaped, gram-negative bacillus that is oxidase positive, catalase positive, and urease positive and grows slowly in culture. Although observed in human tissue at the beginning of the century, it was not cultured until 1982. Because there are significant morphological and genetic differences between this organism and other species of Campylobacter, it will probably be reclassified in a new genus. Current information indicates that the organism primarily resides in the stomach tissue of humans and nonhuman primates and may occasionally spread to the esophagus or other parts of the alimentary tract under appropriate conditions. Significant evidence has accumulated in the last several years to show that it causes gastritis, and there is mounting evidence that it may participate in the development of duodenal ulcers. It may also be associated with gastric ulcers and nonulcer dyspepsia. It can be detected in patients by culture of biopsy specimens or histological staining of biopsy tissue. Indirect evidence for the presence of the organism can be obtained by detection of urease in a tissue biopsy specimen, by urea breath tests, or by detection of specific antibody. It may not be necessary to implement these procedures for routine use, however, until the role of the organism can be defined better. Ultimately, the discovery of this organism may lead to radical changes in the diagnosis and treatment of gastric disease.

show abstract

Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents

Cited by 22 publications

References 10 publications

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Mechanisms of antibiotic resistance in Campylobacter species

Campylobacter pylori and gastroduodenal disease

Contact Info

Product

Resources

About